Acta Oncologica Nordic Precision Cancer Medicine Symposium 2023 – merging clinical research and standard healthcare

Authors

  • Elisa Bjørgo MATRIX, Norwegian Centre for Clinical Cancer Research, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway https://orcid.org/0000-0003-3877-7248
  • Gro L. Fagereng Institute for Cancer Research, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway https://orcid.org/0000-0003-2600-6606
  • Hege G. Russnes Institute for Cancer Research, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Department of Pathology, Oslo University Hospital, Oslo, Norway https://orcid.org/0000-0001-8724-1891
  • Sigbjørn Smeland Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway https://orcid.org/0000-0002-5743-8244
  • Kjetil Taskén Institute for Cancer Research, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway https://orcid.org/0000-0003-2841-4697
  • Åslaug Helland MATRIX, Norwegian Centre for Clinical Cancer Research, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway; Institute for Cancer Research, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway https://orcid.org/0000-0002-5520-0275

DOI:

https://doi.org/10.2340/1651-226X.2024.24954

Keywords:

Precision cancer medicine, molecular diagnostics, biomarkers, clinical trials, DRUP-like clinical trials, health economics

Downloads

Download data is not yet available.

References

Pagadala MS, Lui AJ, Zhong AY, Lynch JA, Karunamuni R, Lee KM et al. Agent orange exposure and prostate cancer risk in the million veteran program. Acta Oncol. 2024;63:373-378..

https://doi.org/10.2340/1651-226X.2024.25053 DOI: https://doi.org/10.2340/1651-226X.2024.25053

Niehusmann P, Leske H, Nygaard V, Russnes HG, Zhao S, Latysheva A et al. Desmoplastic non-infantile ganglioglioma mimicking diffuse leptomeningeal glioneuronal tumor: precision diagnostics and therapeutic implications. Acta Oncol. 2024;63:392-394..

https://doi.org/10.2340/1651-226X.2024.31720 DOI: https://doi.org/10.2340/1651-226X.2024.31720

Otterlei Fjørtoft M, Huse K, Rye IH. The tumor immune microenvironment in breast cancer progression. Acta Oncol. 2024;63:359-367..

https://doi.org/10.2340/1651-226X.2024.33008 DOI: https://doi.org/10.2340/1651-226X.2024.33008

Mangat PK, Halabi S, Bruinooge SS, Garrett-Mayer E, Alva A, Janeway KA et al. Rationale and design of the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2018;2018:10.1200..

https://doi.org/10.1200/PO.18.00122 DOI: https://doi.org/10.1200/PO.18.00122

ASCO TAPUR results: https://society.asco.org/research-data/tapur-study/study-results.

van der Velden DL, Hoes LR, van der Wijngaart H, van Berge Henegouwen JM, van Werkhoven E, Roepman P et al. The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs. Nature. 2019;574:127-131..

https://doi.org/10.1038/s41586-019-1600-x DOI: https://doi.org/10.1038/s41586-019-1600-x

Taskén K, F Haj Mohammad S, Fagereng GL, Sørum Falk R, Helland Å, Barjesteh van Waalwijk van Doorn-Khosrovani S et al. PCM4EU & PRIME-ROSE: collaboration for implementation of precision cancer medicine in Europe. Acta Oncol. 2024;63:385-391..

https://doi.org/10.2340/1651-226X.2024.34791 DOI: https://doi.org/10.2340/1651-226X.2024.34791

Haj Mohammad SF, Timmer HJL, Zeverijn LJ, Geurts BS, Spiekman IAC, Verkerk K et al. The evolution of precision oncology: the ongoing impact of the Drug Rediscovery Protocol (DRUP). Acta Oncol. 2024;63:368-372..

https://doi.org/10.2340/1651-226X.2024.34885 DOI: https://doi.org/10.2340/1651-226X.2024.34885

Helland Å, Russnes HG, Fagereng GL, Al-Shibli K, Andersson Y, Berg T et al. Improving public cancer care by implementing precision medi-cine in Norway: IMPRESS-Norway. J Transl Med. 2022;20:225..

https://doi.org/10.1016/j.annonc.2022.07.631 DOI: https://doi.org/10.1016/j.annonc.2022.07.631

Puco K, Fagereng GL, Brabrand S, Niehusmann P, Blix ES, Steinskog ESS et al. IMPRESS-Norway: improving public cancer care by imple-menting precision medicine in Norway; inclusion rates and preliminary results. Acta Oncol. 2024;63:379-384..

https://doi.org/10.2340/1651-226X.2024.28322 DOI: https://doi.org/10.2340/1651-226X.2024.28322

Kringelbach T, Højgaard M, Rohrberg K, Spanggaard I, Laursen BE, Ladekarl M et al. ProTarget: a Danish Nationwide Clinical Trial on Tar-geted Cancer Treatment based on genomic profiling - a national, phase 2, prospective, multi-drug, non-randomized, open-label bas-ket trial. BMC Cancer. 2023;23:182..

https://doi.org/10.1186/s12885-023-10632-9 DOI: https://doi.org/10.1186/s12885-023-10632-9

Jalkanen K, Alanne E, Iivanainen S, Kääriäinen O-S, Tanner M, Auranen A et al. A national precision cancer medicine implementation initia-tive for Finland. Acta Oncol. 2024;63:395-397..

https://doi.org/10.2340/1651-226X.2024.32661 DOI: https://doi.org/10.2340/1651-226X.2024.32661

Verlingue L, Deserve M, Polito M, Garin G, Rodriguez C, Qing W et al. The French multicentric molecular analysis platforms and personal-ized medicine trials MOST, MOST Plus and MEGAMOST. Acta Oncol. 2024:63:411-417..

https://doi.org/10.2340/1651-226X.2024.32745 DOI: https://doi.org/10.2340/1651-226X.2024.32745

Mainoli B, Assis J, Dinis J, Rui H, Oliveira J. Pioneering the implementation of a precision oncology strategy in Portugal: the Precision Oncology Platform trial. Acta Oncol. 2024;63:482-486.

https://doi.org/10.2340/1651-226X.2023.33322 DOI: https://doi.org/10.2340/1651-226X.2023.33322

Toth E, Kürönya Z, Soós E, Pintér T, Butz H, Horvath Z et al. Application of comprehensive molecular genetic profiling in precision cancer medicine, Hungarian experiences. Acta Oncol. 2024;63:433-440.

https://doi.org/10.2340/1651-226X.2024.39918 DOI: https://doi.org/10.2340/1651-226X.2024.39918

Downloads

Published

2024-06-23

How to Cite

Bjørgo, E., Fagereng, G. L., Russnes, H. G., Smeland, S., Taskén, K., & Helland, Åslaug. (2024). Acta Oncologica Nordic Precision Cancer Medicine Symposium 2023 – merging clinical research and standard healthcare. Acta Oncologica, 63(1), 487–490. https://doi.org/10.2340/1651-226X.2024.24954

Issue

Vol. 63 (2024): Acta Oncologica

Section

Editorial

Categories

License

Copyright (c) 2024 Elisa Bjørgo, Gro L. Fagereng, Hege G. Russnes, Sigbjørn Smeland, Kjetil Taskén, Åslaug Helland

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.